FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave

Similar documents
PET CT for Staging Lung Cancer

PET/CT in lung cancer

PET/CT Frequently Asked Questions

An Update: Lung Cancer

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Lung Cancer Staging: The Revised TNM Classification

The 8th Edition Lung Cancer Stage Classification

Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer

Radiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh

Mediastinal Staging. Samer Kanaan, M.D.

FDG PET/CT in Lung Cancer Read with the experts. Homer A. Macapinlac, M.D.

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09

North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer

The Role of PET / CT in Lung Cancer Staging

Dr Sneha Shah Tata Memorial Hospital, Mumbai.

GUIDELINES FOR CANCER IMAGING Lung Cancer

The 7th Edition of TNM in Lung Cancer.

Chirurgie beim oligo-metastatischen NSCLC

Colorectal Cancer and FDG PET/CT

Surgical management of lung cancer

Lung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.

Prostate Case Scenario 1

GROUP 1: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases. Including: Excluding:

The Itracacies of Staging Patients with Suspected Lung Cancer

MEDIASTINAL STAGING surgical pro

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

F NaF PET/CT in the Evaluation of Skeletal Malignancy

Imaging in gastric cancer

Larry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017

Role of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City

PET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET

42 yr old male with h/o Graves disease and prior I 131 treatment presents with hyperthyroidism and undetectable TSH. 2 hr uptake 20%, 24 hr uptake 50%

Positron Emission Tomography in Lung Cancer

North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma

Video-Mediastinoscopy Thoracoscopy (VATS)

CT PET SCANNING for GIT Malignancies A clinician s perspective

Utility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC)

Radiology Pathology Conference

Collaborative Stage. Site-Specific Instructions - LUNG

RF Ablation: indication, technique and imaging follow-up

THE ROLE OF CONTEMPORARY IMAGING AND HYBRID METHODS IN THE DIAGNOSIS OF CUTANEOUS MALIGNANT MELANOMA(CMM) AND MERKEL CELL CARCINOMA (MCC)

Update in Lymphoma Imaging

and Strength of Recommendations

Imaging of Lung Cancer: A Review of the 8 th TNM Staging System

EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI

When do you need PET/CT or MRI in early breast cancer?

AJCC-NCRA Education Needs Assessment Results

Esophageal Cancer. What is the value of performing PET scan routinely for staging of esophageal cancers

ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London

Bronchogenic Carcinoma

Update on RECIST and Staging of Common Pediatric Tumors Ethan A. Smith, MD

STAGING AND FOLLOW-UP STRATEGIES

Thyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.

FDG-PET/CT in Gynaecologic Cancers

Lung Cancer-a primer. Sai Yendamuri, MD Professor and Chair, Dept of Thoracic Surgery,RPCI,Buffalo

PET/CT F-18 FDG. Objectives. Basics of PET/CT Imaging. Objectives. Basic PET imaging

Chest Radiology Interpretation: Findings of Tuberculosis

FieldStrength. Leuven research is finetuning. whole body staging

Lung 8/7/14. Collecting Cancer Data: Lung NAACCR Webinar Series. August 7, 2014

PLACE LABEL HERE. Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form. RTOG Study No.

Dr J K Jekel Dept. Surgery University of Pretoria

THORACIC MALIGNANCIES

B REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Master Class: Fundamentals of Lung Cancer

B REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment

Disclosure. Acknowledgement. What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Rectal cancer imaging. None

SELF-ASSESSMENT MODULE REFERENCE SPR 2018 Oncologic Imaging Course Adrenal Tumors November 10, :00 12:10 p.m.

The Diagnostic Value of PET/CT in Breast Cancer Recurrence and Metastases

Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer

THE EFFECT OF USING PET-CT FUSION ON TARGET VOLUME DELINEATION AND DOSE TO ORGANS AT RISK IN 3D RADIOTHERAPY PLANNING OF PATIENTS WITH NSSLC

Staging Colorectal Cancer

ROLE OF PET-CT SCAN IN LOCALLY ADVANCED HEAD & NECK CANCER: A Prospective Study

Mediastinal Tumors: Imaging

Controversies in management of squamous esophageal cancer

Triage of Limited Versus Extensive Disease on 18 F-FDG PET/CT Scan in Small Cell lung Cancer

Lugano classification: Role of PET-CT in lymphoma follow-up

Hybrid Imaging SPECT/CT PET/CT PET/MRI. SNMMI Southwest Chapter Aaron C. Jessop, MD

WHITE PAPER - SRS for Non Small Cell Lung Cancer

Whole Body MRI. Dr. Nina Tunariu. Prostate Cancer recurrence, progression and restaging

2004 SNM Mid-Winter Educational Symposium

PET/CT in breast cancer staging

PET/CT in Breast Cancer

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT LYMPHOMA CHAPTER 11B REVISED: SEPTEMBER 2016

Early and locally advanced non-small-cell lung cancer (NSCLC)

Approach to Pulmonary Nodules

Case 1: Early Stage NSCLC. Dr. Dhar Dr. Coughlin Dr. Kay Dr. Hirmiz

Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer

Boot Camp Case Scenarios

Histopathology of NSCLC, IHC markers and ptnm classification

Low risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer

Head & Neck Clinical Sub Group. Network Agreed Imaging Guidelines for UAT and Thyroid Cancer. Measure Nos: 11-1C-105i & 11-1C-106i

An Introduction to PET Imaging in Oncology

Treatment of oligometastatic NSCLC

Adam J. Hansen, MD UHC Thoracic Surgery

8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC

Transcription:

FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave

FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease. FDG PET/CT is valuable in both locoregional nodal (mediastinal) and distant staging. The addition of FDG PET/CT to the conventional work-up will prevent unnecessary surgery in one out of five patients (1) and results in changing stage from that determined by conventional modalities in over half of patients (2).

FDG PET/CT Staging of Lung Cancer In NSCLC, FDG-PET/CT is typically acquired from the base of the skull to the proximal thighs. This field-of-view is designed to acquire data over the expected red marrow distribution, thereby covering the dominant potential sites of osseous, as well as visceral and nodal metastasis.

Lababede O, Chest 2011; 139: 183-189

TNM Staging of Lung Cancer

FDG PET/CT - T STAGING T classification is designed to evaluate the primary lung tumour by determining the size of the primary tumour as measured in the long-axis diameter, extent of local invasion of the primary tumour, and presence or absence of satellite nodules

CAN FDG PET/CT IMPROVE OVER DEDICATED CT ALONE FOR DETERMINATION OF T STAGE? Usually NO Insufficient resolution to determine size and extent of local invasion Rely on dedicated CT for this MRI not definitely better

The primary tumour is very difficult to visualize on CT. Corresponding PET-CT image shows nice delineation between the tumour mass and the distal atelectatic lung. RT PLANNING

PET/CT also improves detection of subtle areas of invasion that may be occult on CT alone. CT scan shows large right upper lobe mass that is contiguous with pleura. Appearance is suspicious for chest wall involvement but not diagnostic. PET/CT shows mild increased uptake in overlying pleural fat (arrow). Chest wall invasion was suggested and confirmed at surgery.

Likely T2 NSCLC on conventional staging Left vocal cord palsy indicates left recurrent laryngeal nerve involvement due to mediastinal invasion (T3)

N Staging Lymph node status (N staging ) is of great importance to determining the resectability of a tumour

CT - N Staging CT has clear shortcomings in the accurate detection of lymph node metastases. In CT a lymph node is considered to be abnormal if its short-axis diameter is more than 1 cm. However, this method has proved inaccurate. In one study, 44 % (107/405) of metastatic nodes measured <1cm, whereas an even larger percentage 77 % of patients (101/139) without metastasis had enlarged nodes measuring greater than 1 cm in the short axis.

PET-CT has been shown to be substantially more sensitive and specific in the detection and characterization of metastases to mediastinal lymph nodes. positive predictive value 78%, negative predictive value 91% and accuracy 87%, (superior to either modality alone).

FDG PET/CT - N Staging Limitations The main limitations of FDG-PET for N staging false-negative - microscopic lymph node involvement - low tumour metabolic activity false-positive - presence of infection - noninfectious inflammation LLL NSCLC - T1b Bilateral Hila and Mediastinal Nodes - Sarcoidosis

PET MEDIASTINAL STAGING PET POSITIVE The false positive rate of PET in the mediastinum is 13-22%. Positive PET results should be confirmed by mediastinal lymph node sampling before excluding surgery as an option. PET is useful in guiding mediastinal node sampling

PET MEDIASTINAL STAGING PET NEGATIVE The false negative rate of PET in the mediastinum is 5 to 8% for a peripheral tumour compared with an average false-negative rate for invasive mediastinal staging of 9%. Invasive mediastinal staging can potentially be avoided before thoracotomy if PET is negative in a <1cm node.

PET MEDIASTINAL STAGING META-ANALYSIS In a meta-analysis of 14 studies of patients with NSCLC, de Langen and colleagues reported that the likelihood for malignancy in an FDG nonavid lymph node was 5% when 10 to 15 mm in diameter 21% when > 15 mm, whereas the likelihood for an FDG avid node was 62% when 10 to 15 mm 90% when > 15 mm.

STAGING OF LUNG CANCER M STAGE M1a (Intra-thoracic Metastases) Malignant pleural or pericardial effusion, malignant pleural nodules, or satellite nodules in contralateral lung M1b (Distant Metastases) Metastasize to almost every organ but mainly to brain, adrenals, bone, liver and distant nodes.

STAGING OF LUNG CANCER M STAGE FDG PET/CT detected occult extrathoracic metastases in upto 24% of patients selected for curative resection Lung Cancer Upstaged from M0 to M1b Bony, Adrenal and Liver Metastases on PET/CT MacManusMP,HicksRJ,MatthewsJP,etal: High rate of detection of unsuspected distant metastases by pet in apparent stageiii non small-cell lung cancer: Implications for radical radiation therapy. Int JRadiatOncol Biol Phys50(2):287-293, 2001

BONE /MARROW METASTASES Bone metastasis is present in 20%-30% of patients at the initial diagnosis of lung cancer. FDG PET Sensitivity 92%, specificity 98%. Compared with bone scan, FDG PET/CT is equal or greater in sensitivity and more specific for the diagnosis of bone marrow metastases from lung cancer. FDG-PET/CT can detect metastases before destruction of bone has occurred. Qu X, Huang X, Yan W, et al. A meta-analysis of (18)FDG-PET-CT, (18)FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol 2012; 81(5):1007 15.

BONE / MARROW METASTASES Tc 99m MDP Bone Scan NaF PET/CT Bone Scan Bone scan has reduced sensitivity in lytic bony metastases

ADRENAL METASTASES Right adrenal adenoma Adrenal metastases are detected in upto 20% of patients with NSCLC. CT has a reported sensitivity, specificity, and accuracy of 60%,80%,and77%, respectively. Left adrenal metastasis FDG-PET/CT is more accurate in detecting adrenal metastases. In a meta-analysis that included 1391 lesions (824 benign and 567 malignant), FDG-PET had a reported sensitivity and a specificity of 97% and 91%,respectively.

BRAIN METASTASIS MRI of the brain remains the method of choice for detecting cerebral metastasis. Contrast-enhanced CT is the most commonly performed procedure in search of brain metastases in spite of the fact that MRI with contrast injection has a greater sensitivity than CT. PET- Sensitivity 60%. Cannot substitute dedicated CT or MRI.

STAGING OF NSCLC PET/CT/MRI T2N1 on CT T2M1b on PET/CT + MRI

Metastatic disease identified by PET requires additional confirmation particularly if there is a single lesion T1a N0?M1b NSCLC Left adrenal Phaeochromocytoma

PET/CT STAGING OF LUNG CARCINOID Neuroendocrine tumours vary in differentiation and glucose metabolism Ga 68-DOTATATE PET/CT 22 Aug 2014 F-18 FDG PET/CT 11 Aug 2014